文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病

幽门螺杆菌根除治疗对功能性消化不良的疗效:更新的系统综述与荟萃分析

Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis.
PubMed 文献 · Gut · 2022-01-12

该系统综述与荟萃分析纳入29项随机对照试验共6781例幽门螺杆菌阳性的功能性消化不良成人患者,评估根除治疗对症状治愈和改善的影响。根除治疗在症状治愈(RR=0.91,95%CI 0.88-0.94,NNT=14)和改善(RR=0.84,95%CI 0.78-0.91,NNT=9)上均优于对照,但不良事件更常见。作者结论为高质量证据提示根除治疗带来 modest 获益。

要点

  • 根除治疗组症状未治愈风险为对照组的0.91倍(95%CI 0.88-0.94),NNT=14(95%CI 11-21)。
  • 根除治疗组症状未改善风险为对照组的0.84倍(95%CI 0.78-0.91),NNT=9(95%CI 7-17)。
  • 根除成功者症状改善或治愈的RR=0.65(95%CI 0.52-0.82),NNT=4.5(95%CI 3-9)。

核心结论

  • 高质量证据提示幽门螺杆菌根除治疗可促进功能性消化不良症状的治愈和改善,但获益幅度 modest。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2021年10月的医学文献,纳入29项随机对照试验,共6781例幽门螺杆菌阳性的功能性消化不良成人患者,随访≥3个月。

主要发现

  • 根除治疗在症状治愈上优于对照(症状未治愈的RR=0.91,95%CI 0.88-0.94,NNT=14,95%CI 11-21)。
  • 根除治疗在症状改善上优于对照(症状未改善的RR=0.84,95%CI 0.78-0.91,NNT=9,95%CI 7-17)。
  • 根除率与功能性消化不良改善或治愈的RR之间无显著相关性(Pearson相关系数=-0.23,p=0.907)。
  • 根除成功患者的效应大于根除失败患者(RR=0.65,95%CI 0.52-0.82,NNT=4.5,95%CI 3-9)。
  • 根除治疗组不良事件更常见(RR=2.19,95%CI 1.10-4.37),导致退出的不良事件也更常见(RR=2.60,95%CI 1.47-4.58)。

关键数值与推荐

  • 对照臂接受抑酸治疗或促动力药,加或不加安慰剂抗生素,或仅安慰剂。
  • 症状未治愈的RR=0.91(95%CI 0.88-0.94),NNT=14(95%CI 11-21)。
  • 症状未改善的RR=0.84(95%CI 0.78-0.91),NNT=9(95%CI 7-17)。
  • 根除成功者RR=0.65(95%CI 0.52-0.82),NNT=4.5(95%CI 3-9)。
  • 不良事件RR=2.19(95%CI 1.10-4.37),导致退出的不良事件RR=2.60(95%CI 1.47-4.58)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Functional dyspepsia (FD) is a chronic disorder that is difficult to treat. Helicobacter pylori may contribute to its pathophysiology. A Cochrane review from 2006 suggested that eradication therapy was beneficial, but there have been numerous randomised controlled trials (RCTs) published since. We evaluated impact of eradication therapy on both cure and improvement of FD, as well as whether any benefit was likely to arise from eradication of H. pylori. DESIGN: We searched the medical literature through October 2021 to identify RCTs examining efficacy of eradication therapy in H. pylori-positive adults with FD. The control arm received antisecretory therapy or prokinetics, with or without placebo antibiotics, or placebo alone. Follow-up was for ≥3 months. We pooled dichotomous data to obtain a relative risk (RR) of symptoms not being cured or symptoms not improving with a 95% CI. We estimated the number needed to treat (NNT). RESULTS: Twenty-nine RCTs recruited 6781 H. pylori-positive patients with FD. Eradication therapy was superior to control for symptom cure (RR of symptoms not being cured=0.91; 95% CI 0.88 to 0.94, NNT=14; 95% CI 11 to 21) and improvement (RR of symptoms not improving=0.84; 95% CI 0.78 to 0.91, NNT=9; 95% CI 7 to 17). There was no significant correlation between eradication rate and RR of FD improving or being cured (Pearson correlation coefficient=-0.23, p=0.907), but the effect was larger in patients with successful eradication of H. pylori than with unsuccessful eradication (RR=0.65; 95% CI 0.52 to 0.82, NNT=4.5, 95% CI 3 to 9). Adverse events (RR=2.19; 95% 1.10 to 4.37) and adverse events leading to withdrawal (RR=2.60; 95% CI 1.47 to 4.58) were more common with eradication therapy. CONCLUSION: There is high quality evidence to suggest that H. pylori eradication therapy leads to both cure and improvement in FD symptoms, although the benefit is modest.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Ford AC, Tsipotis E, Yuan Y, et al. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut. 2022. PMID: 35022266. doi:10.1136/gutjnl-2021-326583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。